Scarica il documento in formato pdf (556 KB) - ANCE

48
Giornale Italiano di Cardiologia Pratica
It J Practice Cardiol
Dicembre 2003
Aguilò J. Home treatment of deep vein
thrombosis: a two-year experience of a
single institution. Haematologica 1998;
83: 438-41.
12. Lapidus L, Borretzen J, fahlen M,
Thomsen H, Hasseblom S, Larson L,
Nordstrom H, Stigendal L, Waller L.
Home treatment of deep vein thrombosis,
an out-patient treatment model
with once-daily injection of low-molecular-weight
heparin (tinzaparin) in
555 patients. Pathophysiol Haemost
Thromb 2002; 32: 59-66.
13. Schwarz T, Schmidt B, Beyer J, Schroder
HE, Schellong S. Eligibility for home
treatment of deep vein thrombosis: a
prospective study in 202 consecutive patients.
J Vasc Surg 2001; 34: 1065-70.
14.Partsch H, Kechavarz B, Hohn H, Mostbeck
A. The effect of mobilisation of patients
during treatment of thromboembolicdisorders
with low-molecular-weight
heparin. Int Angiol 1997; 16:189-92.
15. Aschwanden M, Labs KH, Engel H,
Schwab A, Jeanneret C, Mueller-Brand
J, Jaeger KA. Acute deep vein thrombosis:
early mobilization does not increase
the frequency of pulmonary embolism.
Thromb Haemost 2001; 85:42-6.
16.Pacouret G, Alison D, Pottier JM, Bertrand
P, Charbonnier B. Free-floating
thrombus and embolic risk in patients
with angiographically confirmed proximal
deep venous thrombosis. Arch Intern
Med 1997; 157: 305-8.
17. Greenfield LJ, Arbor A. Free-floating
thrombus and pulmonary embolism.
Arch Intern Med 1997; 157: 2661.
18.The Matisse Investigators. Fondaparinux
in comparison to (low-molecularweight)
heparin for the initial treatment
of symptomatic deep venous thrombosis
or pulmonary embolism. Blood 2002;
100: 83a.
19. Huisman MV, for the THRIVE Treatment
Study Investigators. Efficacy and safety of
the oral direct thrombin inhibitor ximelagatran
for acute symptomatic deep vein
thrombosis, with or without pulmonary
embolism: a randomized, double-blind,
multinational study. J Thromb Haemost
2003 (Suppl.): OC003.